Story

Sandoz Shares Surge on Strong Biosimilar Sales and Reaffirmed Outlook

ENTHMSVIIDZHZH-TWJAKOHI
Aug 5, 20261 min read
Sandoz Shares Surge on Strong Biosimilar Sales and Reaffirmed Outlook
Text size
Background

Sandoz (SDZ) shares surged more than 6% after the Swiss generics and biosimilars company reported stronger-than-expected second-quarter financial results and reaffirmed its full-year guidance. According to a report from Investing.com, the rally was driven by robust growth in its high-margin biosimilars segment and a significant beat on earnings per share.

Earnings Beat Powers Rally

The company announced second-quarter group net sales of $3.005 billion, edging past the analyst consensus estimate of $2.991 billion. The performance was largely fueled by the biosimilars division, which saw net sales climb 22% year-over-year to $1.022 billion.

Sandoz delivered a more substantial surprise on its bottom line. Half-year earnings per share came in at CHF 1.61, well above the consensus forecast of CHF 1.45, providing a key catalyst for the stock's upward move.

Strategic Shift and Outlook

Sample IUX Markets – In-articleAd

Sandoz management maintained its full-year 2026 forecast, a decision that helped remove a key source of uncertainty for investors. The company continues to project mid-to-high single-digit net sales growth at constant currencies and an expansion of its core EBITDA margin by approximately 100 basis points.

The results also underscored the company's ongoing strategic shift toward higher-margin products. Biosimilars accounted for 34% of total Q2 net sales, an increase from 30% in the same period a year earlier, highlighting progress in its move toward more complex biological medicines.

Market and Index Catalysts

The stock's advance was supported by a modestly positive tone in global equity markets. More structurally, Sandoz has seen increased institutional interest following its selection for inclusion in Switzerland's benchmark Swiss Market Index (SMI), which will be effective in September 2026. This development is expected to create incremental demand for the stock from index-tracking funds.

Read next

More on Stocks
Back to latest news

LATEST